Save your place

Sign in to WhoBought

Please try again later.

Olema Pharmaceuticals, Inc. (OLMA) institutional ownership

Market cap$365M SectorHealthcare
Funds holding · Q1 2026
212
reported OLMA position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
114 buyers · 98 sellers

Olema Pharmaceuticals, Inc. (OLMA) price and institutional activity

Dates

Q1 2026

$0 bought by 114 investors
FMR LLCState Street +112 more
$0 sold by 98 investors
Vestal Point Capital, LPSamlyn Capital, LLC +96 more
Sign in to see who bought
Bought Sold Totals per quarter; hover a bar for the names.

Olema Pharmaceuticals, Inc. (OLMA) institutional activity · 212

Investor Type Est. change Change Δ Own Date
FMR LLC · Added
Change +5.4M Δ Own +106.8% Date Q1 2026
FMR LLC Added· Q1 2026 +5.4M +106.8% Q1 2026
State Street · Added
Change +2.1M Date Q1 2026
State Street Added· Q1 2026 +2.1M Q1 2026
Siren, L.L.C. · Added
Change +1.5M Date Q1 2026
Siren, L.L.C. Added· Q1 2026 +1.5M Q1 2026
Vestal Point Capital, LP · Reduced
Change −1.2M Date Q1 2026
Vestal Point Capital, LP Reduced· Q1 2026 −1.2M Q1 2026
Cormorant Asset Management, LP · Added
Change +1.1M Date Q1 2026
Cormorant Asset Management, LP Added· Q1 2026 +1.1M Q1 2026
Samlyn Capital, LLC · Exited
Change −1.1M Δ Own −100.0% Date Q1 2026
Samlyn Capital, LLC Exited· Q1 2026 −1.1M −100.0% Q1 2026
Bain Capital Life Sciences Investors, LLC · Reduced
Change −1.0M Date Q1 2026
Bain Capital Life Sciences Investors, LLC Reduced· Q1 2026 −1.0M Q1 2026
Duquesne Family Office LLC New· Q1 2026 +987K Q1 2026
Jennison Associates LLC · Added
Change +858K Date Q1 2026
Jennison Associates LLC Added· Q1 2026 +858K Q1 2026
Two Sigma Investments, LP · Added
Change +776K Δ Own +197.1% Date Q1 2026
Two Sigma Investments, LP Added· Q1 2026 +776K +197.1% Q1 2026
Lightspeed Management Company, L.L.C. · Reduced
Change −576K Date Q1 2026
Lightspeed Management Company, L.L.C. Reduced· Q1 2026 −576K Q1 2026
Eventide Asset Management, LLC · Exited
Change −569K Δ Own −100.0% Date Q1 2026
Eventide Asset Management, LLC Exited· Q1 2026 −569K −100.0% Q1 2026
Morgan Stanley · Added
Change +550K Date Q1 2026
Morgan Stanley Added· Q1 2026 +550K Q1 2026
Vanguard · Added
Change +549K Date Q1 2026
Vanguard Added· Q1 2026 +549K Q1 2026
Holocene Advisors, LP · Exited
Change −506K Δ Own −100.0% Date Q1 2026
Holocene Advisors, LP Exited· Q1 2026 −506K −100.0% Q1 2026
Data through Q1 2026 · filed Jun 2, 2026
15 of 212

Famous investor activity in Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (OLMA) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Bvf Partners L P · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Bvf Partners L P Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Harmon Cyrus · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Harmon Cyrus Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Butitta Cynthia M. · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Butitta Cynthia M. Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Garland J. Scott · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Garland J. Scott Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Hrustanovic Gorjan · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Hrustanovic Gorjan Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Clark Ian T. · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Clark Ian T. Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Larson Yi · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Larson Yi Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Horning Sandra · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Horning Sandra Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Raman Prakash · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Raman Prakash Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Rappaport Andrew · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Rappaport Andrew Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Graham G. Walmsley · Director Grant (A) 30K
Owned 30K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Graham G. Walmsley Director Grant (A) 30K 30K Jun 18, 2026 Jun 23, 2026
Raman Prakash · Director 2 operations 27K
Owned 24K Trade date Apr 28, 2026 Filed date Apr 29, 2026
Raman Prakash Director 2 operations 27K 24K Apr 28, 2026 Apr 29, 2026
Mitchell Shawnte · Officer 2 operations −$606K
Price $24.25–$24.69 Qty −25K Owned 233 Trade date Mar 4, 2026 Filed date Mar 5, 2026
Mitchell Shawnte Officer 2 operations $24.25–$24.69 −25K −$606K 233 Mar 4, 2026 Mar 5, 2026
Mitchell Shawnte · Officer 2 operations 0
Price $4.37 Owned 410K Trade date Mar 4, 2026 Filed date Mar 5, 2026
Mitchell Shawnte Officer 2 operations $4.37 0 410K Mar 4, 2026 Mar 5, 2026
Mitchell Shawnte · Officer Sell −$345K
Price $23.01 Qty −15K Owned 0 Trade date Mar 3, 2026 Filed date Mar 5, 2026
Mitchell Shawnte Officer Sell $23.01 −15K −$345K 0 Mar 3, 2026 Mar 5, 2026
15 of 48
15 of 48 Sign in to continue to older insider transactions.

Olema Pharmaceuticals, Inc. (OLMA) activist and large shareholders

What are Schedules 13D and 13G?

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Biotechnology Value Fund L P 4.7M
% of shares outstanding 117223850.0% Filing date Sep 14, 2023
Biotechnology Value Fund L P 4.7M 117223850.0% Sep 14, 2023
Paradigm Biocapital Advisors LP 5.5M
% of shares outstanding 9.6% Filing date Nov 14, 2024
Paradigm Biocapital Advisors LP 5.5M 9.6% Nov 14, 2024
Janus Henderson Group PLC 7.1M
% of shares outstanding 8.2% Filing date May 15, 2026
Janus Henderson Group PLC 7.1M 8.2% May 15, 2026
Bain Capital Life Sciences Opportunities Iv, L.P. 7.5M
% of shares outstanding 8.2% Filing date May 15, 2026
Bain Capital Life Sciences Opportunities Iv, L.P. 7.5M 8.2% May 15, 2026
Deep Track Capital, LP
% of shares outstanding 7.0% Filing date Nov 14, 2024
Deep Track Capital, LP 7.0% Nov 14, 2024
BlackRock Inc. 3.3M
% of shares outstanding 6.0% Filing date Jan 29, 2024
BlackRock Inc. 3.3M 6.0% Jan 29, 2024
Logos Global Management LP 3.2M
% of shares outstanding 5.8% Filing date Jun 6, 2024
Logos Global Management LP 3.2M 5.8% Jun 6, 2024
Point72 Asset Management, L.P. 3.2M
% of shares outstanding 5.7% Filing date Jun 14, 2024
Point72 Asset Management, L.P. 3.2M 5.7% Jun 14, 2024
8 of 13

Olema Pharmaceuticals, Inc. (OLMA) ownership FAQ

Who owns OLMA?

212 reporting institutions disclosed OLMA position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.